| Literature DB >> 15247437 |
Daria J Hazuda1, Steven D Young, James P Guare, Neville J Anthony, Robert P Gomez, John S Wai, Joseph P Vacca, Larry Handt, Sherri L Motzel, Hilton J Klein, Geethanjali Dornadula, Robert M Danovich, Marc V Witmer, Keith A A Wilson, Lynda Tussey, William A Schleif, Lori S Gabryelski, Lixia Jin, Michael D Miller, Danilo R Casimiro, Emilio A Emini, John W Shiver.
Abstract
We describe the efficacy of L-870812, an inhibitor of HIV-1 and SIV integrase, in rhesus macaques infected with the simian-human immunodeficiency virus (SHIV) 89.6P. When initiated before CD4 cell depletion, L-870812 therapy mediated a sustained suppression of viremia, preserving CD4 levels and permitting the induction of virus-specific cellular immunity. L-870812 was also active in chronic infection; however, the magnitude and durability of the effect varied in conjunction with the pretreatment immune response and viral load. These studies demonstrate integrase inhibitor activity in vivo and suggest that cellular immunity facilitates chemotherapeutic efficacy in retroviral infections.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15247437 DOI： 10.1126/science.1098632
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728